title: Potential Drug Combinations to Reduce Cardiovascular Disease Burden in Diabetes.
abstract: The major cause of death and complications in patients with type 2 diabetes (T2DM) is cardiovascular disease (CVD). More than 60% of all patients with T2DM die of CVD, and an even greater percentage have serious complications. The impact of glucose lowering on cardiovascular complications is a hotly debated issue and recent large clinical trials reported no significant decrease in cardiovascular events with intensive glucose control. Risk remains high even after correcting diabetes-associated dyslipidemia with drugs such as fibrates and niacin. Data from several clinical studies show that postprandial glucose and lipids have a strong predictive value on myocardial infarction (MI) and mortality. However, strategies to reduce postprandial hyperglycemia and/or lipemia through increased utilization of glucose and/or triglycerides (TG) have been shown to not be effective in reducing the CVD burden. In this review, I discus the preferred ways to reduce postprandial glucose and TG with combinations of currently marketed drugs with potential benefit in CVD.
authors.affiliation: Kareus Therapeutics SA, La Chaux-de-Fonds, Switzerland; NeuroPn Therapeutics, GA, Alpharetta, USA. Electronic address: pillarisetti@live.com.
authors.forename: Sivaram
authors.initials: S
authors.lastname: Pillarisetti
mesh_terms: D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D058065:Diabetic Cardiomyopathies / Q000097:blood / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000188:drug therapy / Q000517:prevention & control; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D001786:Blood Glucose